Ostrich Pharma USA Produces Antibodies to Block the Virus that Causes COVID-19

Business Wire: | April 01, 2020

Ostrich Pharma USA Produces Antibodies to Block the Virus that Causes COVID-19
Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sciences at Kyoto Prefectural University and Co-CEO of Ostrich Pharma USA, has injected a genetically engineered pseudovirus into ostriches, and antibodies were purified from their eggs. These antibodies demonstrate a strong ability to neutralize SARS-CoV-2 viruses. Dr. Tsukamoto said: “We have produced ostrich antibodies to many viruses, bacteria, and allergens, but we were pleased to see how quickly the ostriches developed immunity and placed the anti-SARS-CoV-2 antibodies in their eggs. We were even more pleased to see how capable the antibodies were in blocking the virus that causes COVID-19.

Spotlight

Pharmadule, the world leader in modular manufacturing facilities for the pharmaceutical industry, has in recent years been working with Munters to supply humidity controlled facilities for Eli Lilly Indianapolis, Baxter Bloomington USA and Eli Lilly Kinsale Ireland. As part of their expansion plans to meet increasing demand Eli Lily and Baxter expanded their manufacturing facilities by utilizing Pharmadule's modular concept incorporating humidity control systems from Munters MDU, ICA and MX range.

Related News

Novavax, advancing COVID-19 shot, recruits AstraZeneca exec as its chief medical officer

Fiercepharma | June 17, 2020

On the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team. Joining the company's leadership team as chief medical officer is Filip Dubovsky, an AstraZeneca veteran. Dubovsky joins Novavax directly from the British drugmaker, where he served as head of clinical engagement and policy, plus as chief medical officer for clinical affairs. Before that role, he oversaw a portfolio of more than two dozen malaria vaccines at the PATH Malaria Vaccine Initiative. Dubrovsky will be tasked with overseeing development of the company's COVID-19 candidate. The company in late May kicked off a phase 1/2 study of the prospect, and it's been working through steps to scale up its manufacturing in parallel. Aside from its COVID-19 work, the company is getting ready to submit an FDA application for its flu vaccine, NanoFlu.

Read More

BUSINESS INSIGHTS

INNOTECH and OSARO Collaborate to Build a Demonstration AI Picking Robot System for Rohto Pharmaceutical’s Next-generation Smart Factory

INNOTECH and OSARO | January 12, 2022

OSARO Inc. a global leader in the development and provision of advanced robotics automation, and INNOTECH CORPORATION, which provides advanced products for electronics and consumer industries, have announced a collaboration to create an innovative demonstration for Rohto Pharmaceutical Co., Ltd. using AI piece-picking robots. The two companies are jointly providing picking robots and jointly building a system for their introduction into a new factory production line, scheduled for completion in 2022. OSARO will take the lead in providing AI software to improve the efficiency of robot operations, and INNOTECH will provide support from demonstration testing to integration of the AI software. By automating the picking of bottle products, one of the most labor-intensive tasks in the production process, with robots, the collaboration aims to reduce the workload and improve productivity at the Rohto factory. Rohto produces OTC medicines, beauty products and supplements. In the eye care category, sales of OTC eye drops account for more than 40 percent of the Japanese market. “We are honored to have OSARO's picking technology recognized by the next-generation smart factory of Rohto Pharmaceutical Co. We believe that the ability to integrate with existing equipment is a great advantage to create a new model case for Japan’s future factories and warehouses.” OSARO CEO Derik Pridmore Yosuke Kaburaki, Director, INNOTECH CORPORATION stated: “We have been conducting basic experiments with Rohto Pharmaceutical using robots that incorporate OSARO's AI software. In the future, INNOTECH will continue to speed up the integration of OSARO's software technology into Rohto's production process to make it more effective and efficient.” About INNOTECH CORPORATION Yokohama City, Kanagawa Prefecture, Japan INNOTECH provides comprehensive technology and support solutions for customer product development and manufacturing. Since 2000, INNOTECH has engaged in the business of internally developed products, leveraging its technical knowledge, strengthened by its existing and expanding business relationships. Today, INNOTECH continues to evolve as a total solution company, with hardware, software, consulting and support offerings for customers’ design, development, and mass production activities, leading up to the introduction of their final products. About OSARO, San Francisco, CA, USA OSARO designs and deploys robotics automation solutions in the materials handling industry using software-defined robotics. OSARO automation systems bring together advanced machine learning for object recognition with powerful control software that adapts to customer data and environments. The company’s robotic piece-picking solution is optimized for grocery, cosmetic, and e-commerce markets, where key challenges include high SKU inventories, complex packaging, and fragile items requiring delicate handling. OSARO Solutions have been validated by the world’s leading retailers, system integrators, and third-party logistic companies.

Read More

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine

Intravacc | September 08, 2020

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract with base and options that may total US$9.4 million from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68). EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (AFM). Intravacc will develop an inactivated EV D68 vaccine, based on Intravacc's proprietary Vero cell technology, from early product selection through to Phase I clinical testing.

Read More

Spotlight

Pharmadule, the world leader in modular manufacturing facilities for the pharmaceutical industry, has in recent years been working with Munters to supply humidity controlled facilities for Eli Lilly Indianapolis, Baxter Bloomington USA and Eli Lilly Kinsale Ireland. As part of their expansion plans to meet increasing demand Eli Lily and Baxter expanded their manufacturing facilities by utilizing Pharmadule's modular concept incorporating humidity control systems from Munters MDU, ICA and MX range.